Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how ...
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the ...
Avacta Therapeutics, a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumour payloads directly to the tumour, has agreed to sell Launch ...
— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...
LONDON AND PHILADELPHIA - Avacta Therapeutics (AIM: AVCT), a developer of peptide drug conjugates, has entered into an agreement to sell its diagnostic unit, Launch Diagnostics Holdings Limited, to ...
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts Encouraging Progression Free Survival ...
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts Encouraging Progression Free Survival ...
UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN Avacta Announces Agreement to Sell Launch ...
LONDON - Avacta Therapeutics (AIM: AVCT), a developer of peptide drug conjugates for cancer treatment, has reported encouraging results from the Phase 1a dose escalation trial of its lead drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback